Metoflex Tablet
Methocarbamol
750mg
LABATEC-PHARMA SA
| Pack size | 50's (10's Blister x 5) |
|---|---|
| Dispensing mode | POM-R (Dispense maximum for one month) |
| Source | SWITZERLAND |
| Agent | Al ittihad drug store |
| Retail Price | 114.50 AED |
Indications
Metoflex Tablet is used for:
Muscle Spasm, Tetanus
Adult Dose
Oral
Muscle spasm
Adult: Initially: 1.5 g q6hr for 48-72 hours; not to exceed 8 g/day THEN decrease to 4-4.5 g/day divided q4-8hr
Parenteral
1 g IV/IM; additional doses at q8hr until PO; not to exceed 3 g/day
Total parenteral dose should not exceed 3 g/day for >3 days, unless treating tetanus; if condition persists, may repeat therapy after drug-free interval of 48 hr
Intravenous
Tetanus
Adult: Adjunct therapy: Initial 1-2 g IV injection (at 300 mg/min), THEN
Additional 1-2 g IV infusion for total dose of 3 g initially
May repeat 1-2 g IV q6hr until can give NG or PO
Total oral dosage of up to 24 g daily may be needed.
Elderly: Dose may need to be reduced by half.
Child Dose
Tetanus
15 mg/kg/dose IV q6hr PRN or 500 mg/m²/dose; not to exceed 1.8 g/m²/day for 3 days only
Muscle Spasm
<16 years: Safety and efficacy not established
>16 years: 1500 mg PO q6hr for 48-72 hours; not to exceed 8 g/day THEN decrease to 4-4.5 g/day divided q4-8hr
Renal Dose
Renal failure: Not studied; parenteral dosage form contraindicated due to presence of polyethylene glycol
Administration
IV Administration
Direct IV: Administer undiluted at not to exceed 3 mL (=300 mg undiluted)/min
Infusion: Dilute 1 g with up to 250 mL D5W or NS; avoid extravasation, since injection is hypertonic
Administer IV while in recumbent position
Maintain position 15-30 min following infusion
IM Administration
Not to exceed 500 mg (5 mL undiluted) should be given into each gluteal region
Contra Indications
Hypersensitivity, Do not admin parenteral solutions in patients with renal impairment, epilepsy or history of epilepsy. Coma or pre-coma states, brain damage, myasthenia gravis
Precautions
May cause drowsiness/dizziness; patients should not ingest alcohol or other CNS depressants
May take with food to avoid stomach upset
Half-life increases with hepatic impairment
IV formulation not for use in renal impairment (contains polyethylene glycol; injection rate should not exceed 3 mL/min
May interfere with screening tests for 5-HIAA and vanillylmandelic acid (VMA)
Use injection with caution in patients with a history of seizures
Sedative effects potentiated when used with other sedatives
Medication is poorly tolerated in the elderly
Pediatric IV dosing approved only for tetanus
Lactation: Not known if excreted in breast milk; use caution
Pregnancy-Lactation
Pregnancy category: C
Lactation: Not known if excreted in breast milk; use caution
Interactions
Action potentiated by alcohol and other CNS depressants. May inhibit effect of pyridostigmine, use with caution with anticholinesterase agents.
Adverse Effects
Side effects of Methocarbamol :
Nausea, anorexia, fever, headache, blurred vision, lassitude, drowsiness, dizziness, restlesness, anxiety, confusion, convulsions; hypersensitivity reactions e.g. rashes, pruritus, urticaria, angiodema. Parenteral: Flushing and a metallic taste; incoordination, diplopia, nystagmus, vertigo; sloughing and thrombophloebitis at the site of inj.
Potentially Fatal: Parenteral: Syncope, hypotension, bradycardia, anaphylaxis.
Mechanism of Action
Unknown; Methocarbamol is a centrally acting skeletal muscle relaxant whose precise mode of action is not known. It is said to cause general depression of the central nervous system.
Note
Metoflex 750mg Tablet manufactured by LABATEC-PHARMA SA. Its generic name is Methocarbamol. Metoflex is availble in United Arab Emirates.
Farmaco UAE drug index information on Metoflex Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.